Rhabdomyosarcoma. From the laboratory to the clinic

P. J. Houghton; D. N. Shapiro; J. A. Houghton

doi:10.1016/S0031-3955(16)38081-6

Rhabdomyosarcoma. From the laboratory to the clinic

P. J. Houghton
, D. N. Shapiro
, J. A. Houghton

Producción científica: Article › revisión exhaustiva

12 Citas (Scopus)

Resumen

The prospect of identifying and developing new agents for treatment of rhabdomyosarcomas is discussed in the light of current prognosis for children with advanced stage disease. Preliminary attempts to identify tumor-specific agents using in vitro cell culture show potential promise, but as yet remain unproven. The more complex system of identifying therapeutically active agents using human tumor xenografts has demonstrated usefulness. The potential problems associated with this system are discussed.

Idioma original	English (US)
Páginas (desde-hasta)	349-364
Número de páginas	16
Publicación	Pediatric Clinics of North America
Volumen	38
N.º	2
DOI	https://doi.org/10.1016/S0031-3955(16)38081-6
Estado	Published - 1991
Publicado de forma externa	Sí

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Acceder al documento

10.1016/S0031-3955(16)38081-6

Otros archivos y enlaces

Citar esto

@article{e34a39fb89c44962993f1bf19894d91c,

title = "Rhabdomyosarcoma. From the laboratory to the clinic",

abstract = "The prospect of identifying and developing new agents for treatment of rhabdomyosarcomas is discussed in the light of current prognosis for children with advanced stage disease. Preliminary attempts to identify tumor-specific agents using in vitro cell culture show potential promise, but as yet remain unproven. The more complex system of identifying therapeutically active agents using human tumor xenografts has demonstrated usefulness. The potential problems associated with this system are discussed.",

author = "Houghton, \{P. J.\} and Shapiro, \{D. N.\} and Houghton, \{J. A.\}",

note = "Funding Information: *Member, Laboratories for Developmental Therapeutics. Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee tAssistant Member, Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; and Professor, Department of Pediatrics, University of Tennessee Center for Health Sciences, Memphis, Tennessee *Member, Laboratories for Developmental Therapeutics, Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee This work was supported in part by American Cancer Society award CH-423, and PHS grants CA 23099 and CA 21765 from the National Cancer Institute and by American Lebanese Syrian Associated Charities (ALSAC).",

year = "1991",

doi = "10.1016/S0031-3955(16)38081-6",

language = "English (US)",

volume = "38",

pages = "349--364",

journal = "Pediatric Clinics of North America",

issn = "0031-3955",

publisher = "W.B. Saunders",

number = "2",

}

TY - JOUR

T1 - Rhabdomyosarcoma. From the laboratory to the clinic

AU - Houghton, P. J.

AU - Shapiro, D. N.

AU - Houghton, J. A.

N1 - Funding Information: *Member, Laboratories for Developmental Therapeutics. Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee tAssistant Member, Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee; and Professor, Department of Pediatrics, University of Tennessee Center for Health Sciences, Memphis, Tennessee *Member, Laboratories for Developmental Therapeutics, Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee This work was supported in part by American Cancer Society award CH-423, and PHS grants CA 23099 and CA 21765 from the National Cancer Institute and by American Lebanese Syrian Associated Charities (ALSAC).

PY - 1991

Y1 - 1991

N2 - The prospect of identifying and developing new agents for treatment of rhabdomyosarcomas is discussed in the light of current prognosis for children with advanced stage disease. Preliminary attempts to identify tumor-specific agents using in vitro cell culture show potential promise, but as yet remain unproven. The more complex system of identifying therapeutically active agents using human tumor xenografts has demonstrated usefulness. The potential problems associated with this system are discussed.

AB - The prospect of identifying and developing new agents for treatment of rhabdomyosarcomas is discussed in the light of current prognosis for children with advanced stage disease. Preliminary attempts to identify tumor-specific agents using in vitro cell culture show potential promise, but as yet remain unproven. The more complex system of identifying therapeutically active agents using human tumor xenografts has demonstrated usefulness. The potential problems associated with this system are discussed.

UR - https://www.scopus.com/pages/publications/0025779957

UR - https://www.scopus.com/pages/publications/0025779957#tab=citedBy

U2 - 10.1016/S0031-3955(16)38081-6

DO - 10.1016/S0031-3955(16)38081-6

M3 - Article

C2 - 2006081

AN - SCOPUS:0025779957

SN - 0031-3955

VL - 38

SP - 349

EP - 364

JO - Pediatric Clinics of North America

JF - Pediatric Clinics of North America

IS - 2

ER -

Rhabdomyosarcoma. From the laboratory to the clinic

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto